MorphoSys to Present at Four Investor Conferences in June

MorphoSys to Present at Four Investor Conferences in June

MUNICH, Germany, June 2, 2014 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR;
Prime Standard Segment, TecDAX; OTC: MPSYY) will present at the following
investor conferences in June:

Jefferies 2014 Global Healthcare Conference
Date: 4 June 2014, 9:00 a.m. EDT (3:00 p.m. CEST, 2:00 p.m. BST)
Venue:New York, USA
Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG,Dr. Arndt
Schottelius, Chief Development Officer of MorphoSys AG,Dr. Claudia
Gutjahr-Löser, Head of Corporate Communications & IR

Goldman Sachs 35^th Annual Global Healthcare Conference
Date: 10 June 2014, 2:00 p.m. PDT (11:00 p.m. CEST, 10:00 a.m. BST)
Venue: Rancho Palos Verdes, CA, USA
Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG,Dr.
Claudia Gutjahr-Löser, Head of Corporate Communications & IR

Deutsche Bank dbAccess German, Swiss & Austrian Conference
Date: 13 June 2014, 9:30 a.m. CEST (3:30 a.m. EDT, 8:30 a.m. BST)
Venue: Berlin, Germany
Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG

J.P. Morgan Cazenove 2^nd European Healthcare Conference
Date: 26 June 2014
Venue: London, UK
Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG, Dr. Claudia
Gutjahr-Löser, Head of Corporate Communications & IR

A PDF version of all presentations will be provided at www.morphosys.com.

The link to webcasts will be filed under www.morphosys.com/conference-calls.

About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 80 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.
With its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys
is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular
updates about MorphoSys, visit http://www.morphosys.com.

HuCAL^®, HuCAL  GOLD^®,  HuCAL PLATINUM^®,  CysDisplay^®,  RapMAT^®,  arYla^®, 
Ylanthia^® and  100 billion  high potentials^®  are registered  trademarks  of 
MorphoSys AG.

Slonomics^® is  a  registered  trademark  of  Sloning  BioTechnology  GmbH,  a 
subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements concerning  the 
MorphoSys group of companies. The forward-looking statements contained  herein 
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties.  Should actual conditions  differ from the  Company's 
assumptions, actual results  and actions  may differ  from those  anticipated. 
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.

For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR

Mario Brkulj
Associate Director Corporate Communications & IR

Alexandra Goller
Specialist Corporate Communications & IR

Jessica Rush
Specialist Corporate Communications & IR

Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com

Conference Announcement June http://hugin.info/130295/R/1789582/615131.pdf

HUG#1789582
 
Press spacebar to pause and continue. Press esc to stop.